December 20, 2017 / 11:05 PM / a year ago

BRIEF-Denali Therapeutics Announces Advancement And Expansion Of Its LRRK2 Inhibitor Clinical Program For Parkinson’S Disease

Dec 20 (Reuters) - Denali Therapeutics Inc:

* DENALI THERAPEUTICS ANNOUNCES ADVANCEMENT AND EXPANSION OF ITS LRRK2 INHIBITOR CLINICAL PROGRAM FOR PARKINSON’S DISEASE

* DENALI THERAPEUTICS - BASED ON REVIEW OF CLINICAL DATA FROM ONGOING STUDY ON LRRK2 INHIBITOR, FDA REMOVED PARTIAL CLINICAL HOLD

* DENALI THERAPEUTICS SAYS PLANS TO SELECT EITHER DNL201 OR DNL151 TO MOVE INTO STUDIES IN PARKINSON'S DISEASE PATIENTS CARRYING A LRRK2 MUTATION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below